LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Denali Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

20.59

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.33

Max

20.88

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.6M

-129M

EPS

-0.73

Darbinieki

503

EBITDA

8.9M

-125M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+60.91% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 4. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

70M

3.3B

Iepriekšējā atvēršanas cena

20.59

Iepriekšējā slēgšanas cena

20.59

Ziņu noskaņojums

By Acuity

50%

50%

150 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Denali Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 17. marts 22:42 UTC

Peļņas

Prudential PLC 2025 Adjusted Operating Profit Rises

2026. g. 17. marts 21:40 UTC

Peļņas

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

2026. g. 17. marts 23:56 UTC

Tirgus saruna

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

2026. g. 17. marts 23:46 UTC

Tirgus saruna

Nikkei May Rise After Recent Selloffs -- Market Talk

2026. g. 17. marts 23:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 17. marts 23:42 UTC

Tirgus saruna

RBA's Return to Policy Tightening Will Work -- Market Talk

2026. g. 17. marts 23:38 UTC

Tirgus saruna

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

2026. g. 17. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 17. marts 23:24 UTC

Tirgus saruna

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

2026. g. 17. marts 22:22 UTC

Tirgus saruna

BHP Hands Reins to Growth-Focused Executive -- Market Talk

2026. g. 17. marts 22:20 UTC

Peļņas

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

2026. g. 17. marts 22:20 UTC

Peļņas

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

2026. g. 17. marts 22:07 UTC

Peļņas

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

2026. g. 17. marts 22:05 UTC

Peļņas

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

2026. g. 17. marts 22:04 UTC

Peļņas

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

2026. g. 17. marts 22:03 UTC

Peļņas

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

2026. g. 17. marts 22:01 UTC

Peļņas

ZTO Express (Cayman) 4Q EPS 47c >ZTO

2026. g. 17. marts 21:26 UTC

Peļņas

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

2026. g. 17. marts 21:09 UTC

Peļņas

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

2026. g. 17. marts 21:08 UTC

Peļņas

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

2026. g. 17. marts 21:08 UTC

Peļņas

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026. g. 17. marts 21:07 UTC

Peļņas

Couche-Tard 3Q EPS 82c >ATD.T

2026. g. 17. marts 21:06 UTC

Peļņas

Couche-Tard 3Q Rev $21.8B >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Adj EPS 81c >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Rev $21.8B >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q EPS 82c >ATD.T

2026. g. 17. marts 21:05 UTC

Peļņas

Couche-Tard 3Q Net $757.2M >ATD.T

2026. g. 17. marts 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Energy & Utilities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Denali Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

60.91% augšup

Prognoze 12 mēnešiem

Vidējais 33.1 USD  60.91%

Augstākais 40 USD

Zemākais 25 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

12

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

13.355 / 16.44Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Neutral Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

150 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat